In humans, decreased circulating OXT levels have been recorded in individuals with obesity or diabetes, and OXT administration is currently being explored as a treatment for obesity-related comorbidities43 (Supplementary Data 4). The gene discussed is OXT; the disease is diabetes mellitus.